196 related articles for article (PubMed ID: 33162523)
1. [Updates in treatment strategies for follicular lymphoma].
Fukuhara N
Rinsho Ketsueki; 2020; 61(9):1252-1258. PubMed ID: 33162523
[TBL] [Abstract][Full Text] [Related]
2. [The current therapeutic landscape for follicular lymphoma].
Kobayashi T
Rinsho Ketsueki; 2021; 62(8):1070-1076. PubMed ID: 34497193
[TBL] [Abstract][Full Text] [Related]
3. [Treatment strategies for follicular lymphoma].
Fukuhara N
Rinsho Ketsueki; 2023; 64(9):1019-1025. PubMed ID: 37899178
[TBL] [Abstract][Full Text] [Related]
4. Current approaches and future perspectives for advanced-stage follicular lymphoma with a low tumor burden.
Fukuhara N; Ishizawa K
Jpn J Clin Oncol; 2019 Apr; 49(4):306-310. PubMed ID: 30715424
[TBL] [Abstract][Full Text] [Related]
5. [Follicular lymphoma: recent advances].
Ando K
Rinsho Ketsueki; 2018; 59(10):2104-2108. PubMed ID: 30305515
[TBL] [Abstract][Full Text] [Related]
6. [Standard treatment and future perspectives for follicular lymphoma].
Kameoka Y
Rinsho Ketsueki; 2022; 63(9):1135-1144. PubMed ID: 36198539
[TBL] [Abstract][Full Text] [Related]
7. [Management strategy for follicular lymphoma].
Fukuhara N
Rinsho Ketsueki; 2017; 58(10):2020-2025. PubMed ID: 28978844
[TBL] [Abstract][Full Text] [Related]
8. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
Matarasso S; Assouline S
Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab.
Ferrer A; López-Guillermo A; Montoto S; Estrach T; Colomo L; Montserrat E
Ann Hematol; 2001 Aug; 80(8):479-81. PubMed ID: 11563595
[TBL] [Abstract][Full Text] [Related]
10. Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.
Seiler T; Hiddemann W; Dreyling M
Immunotherapy; 2009 Nov; 1(6):1015-24. PubMed ID: 20635916
[TBL] [Abstract][Full Text] [Related]
11. [Low grade lymphoma: research progress and questions about treatment].
Ishizawa K
Rinsho Ketsueki; 2015 Oct; 56(10):2039-46. PubMed ID: 26458443
[TBL] [Abstract][Full Text] [Related]
12. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
13. Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?
Pettengell R
Drugs; 2009; 69(13):1727-37. PubMed ID: 19719330
[TBL] [Abstract][Full Text] [Related]
14. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
Feuring-Buske M; Kneba M; Unterhalt M; Engert A; Gramatzki M; Hiller E; Trümper L; Brugger W; Ostermann H; Atzpodien J; Hallek M; Aulitzky E; Hiddemann W
Ann Hematol; 2000 Sep; 79(9):493-500. PubMed ID: 11043420
[TBL] [Abstract][Full Text] [Related]
15. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
16. Is observation dead in follicular lymphoma? Still appropriate.
Jacobson CA; Freedman AS
J Natl Compr Canc Netw; 2015 Mar; 13(3):367-70. PubMed ID: 25736012
[TBL] [Abstract][Full Text] [Related]
17. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
Feugier P
Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779
[TBL] [Abstract][Full Text] [Related]
18. [Follicular lymphoma].
Tomita N
Nihon Rinsho; 2014 Mar; 72(3):488-92. PubMed ID: 24724409
[TBL] [Abstract][Full Text] [Related]
19. [Follicular lymphoma: first - line selection criteria of treatment].
Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
